Lincoln National Corp decreased its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 4.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,842 shares of the medical instruments supplier’s stock after selling 194 shares during the period. Lincoln National Corp’s holdings in Becton, Dickinson and Company were worth $951,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Defined Wealth Management LLC raised its stake in Becton, Dickinson and Company by 4.4% in the 4th quarter. Defined Wealth Management LLC now owns 950 shares of the medical instruments supplier’s stock worth $242,000 after acquiring an additional 40 shares during the last quarter. Delta Financial Group Inc. raised its stake in Becton, Dickinson and Company by 4.2% in the 1st quarter. Delta Financial Group Inc. now owns 1,010 shares of the medical instruments supplier’s stock worth $250,000 after acquiring an additional 41 shares during the last quarter. Auxano Advisors LLC raised its stake in Becton, Dickinson and Company by 2.2% in the 1st quarter. Auxano Advisors LLC now owns 1,942 shares of the medical instruments supplier’s stock worth $481,000 after acquiring an additional 41 shares during the last quarter. Cozad Asset Management Inc. grew its position in Becton, Dickinson and Company by 1.5% during the 1st quarter. Cozad Asset Management Inc. now owns 2,768 shares of the medical instruments supplier’s stock worth $685,000 after purchasing an additional 41 shares during the period. Finally, Stratos Wealth Advisors LLC grew its position in Becton, Dickinson and Company by 1.0% during the 1st quarter. Stratos Wealth Advisors LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $1,052,000 after purchasing an additional 43 shares during the period. Hedge funds and other institutional investors own 85.57% of the company’s stock.
Becton, Dickinson and Company Price Performance
NYSE:BDX opened at $264.84 on Monday. Becton, Dickinson and Company has a 52 week low of $215.90 and a 52 week high of $269.06. The company has a quick ratio of 0.81, a current ratio of 1.31 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $75.22 billion, a PE ratio of 49.69, a price-to-earnings-growth ratio of 2.15 and a beta of 0.57. The stock’s 50-day moving average price is $254.14 and its 200-day moving average price is $250.33.
Becton, Dickinson and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 30th. Investors of record on Friday, June 9th were issued a $0.91 dividend. This represents a $3.64 annualized dividend and a yield of 1.37%. The ex-dividend date was Thursday, June 8th. Becton, Dickinson and Company’s payout ratio is 68.29%.
Wall Street Analysts Forecast Growth
BDX has been the topic of several analyst reports. Evercore ISI cut their price target on Becton, Dickinson and Company from $280.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 4th. Barclays increased their price target on Becton, Dickinson and Company from $282.00 to $284.00 in a research report on Monday, May 8th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, July 18th. Finally, Piper Sandler raised Becton, Dickinson and Company from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $260.00 to $290.00 in a research report on Friday, May 5th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $276.38.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Recommended Stories
- Five stocks we like better than Becton, Dickinson and Company
- MarketBeat Week in Review – 7/17 – 7/21
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
